New drug tested in kids to control kidney disease complications
NCT ID NCT07494045
Summary
This study is testing an extended-release capsule called CTAP101 in children under 18 who have chronic kidney disease, a related hormone imbalance, and low vitamin D. The main goals are to see how the drug moves through the body, how it works, and if it is safe and tolerable. About 40 participants will take the capsules daily at bedtime for 8 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY HYPERPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OPKO Site
Kansas City, Missouri, 64108, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
OPKO Site
Columbus, Ohio, 43205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
OPKO Site
Philadelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
OPKO Site
Greenville, South Carolina, 29615, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
OPKO Site
Madison, Wisconsin, 53562, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.